Published in Can Fam Physician on November 01, 2004
Clostridium difficile prevalence rates in a large healthcare system stratified according to patient population, age, gender, and specimen consistency. Eur J Clin Microbiol Infect Dis (2011) 1.01
Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Infect Immun (2012) 0.89
The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine (2010) 0.87
The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction. PLoS One (2013) 0.82
Antibiotic-associated diarrhea: candidate organisms other than Clostridium difficile. Korean J Intern Med (2008) 0.81
Isolation of toxigenic Clostridium difficile from ready-to-eat salads by multiplex polymerase chain reaction in Isfahan, Iran. Adv Biomed Res (2015) 0.75
Clarification of article on Clostridium difficile--associated colitis. Can Fam Physician (2005) 0.75
Physiological Properties and Salmonella Growth Inhibition of Probiotic Bacillus Strains Isolated from Environmental and Poultry Sources. Int J Bacteriol (2013) 0.75
Clostridium difficile colitis. N Engl J Med (1994) 9.31
Nosocomial acquisition of Clostridium difficile infection. N Engl J Med (1989) 7.72
Clinical practice. Antibiotic-associated diarrhea. N Engl J Med (2002) 7.13
Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet (1989) 4.44
Clostridium difficile-associated diarrhea and colitis. Infect Control Hosp Epidemiol (1995) 4.39
Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol (1997) 3.70
A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA (1994) 3.66
Acquisition of Clostridium difficile by hospitalized patients: evidence for colonized new admissions as a source of infection. J Infect Dis (1992) 3.37
Prospective randomised trial of metronidazole versus vancomycin for Clostridium-difficile-associated diarrhoea and colitis. Lancet (1983) 3.24
Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol (2002) 3.24
Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982-1991. Infect Control Hosp Epidemiol (1994) 3.06
Clostridium difficile toxin B is more potent than toxin A in damaging human colonic epithelium in vitro. J Clin Invest (1995) 2.91
Epidemics of diarrhea caused by a clindamycin-resistant strain of Clostridium difficile in four hospitals. N Engl J Med (1999) 2.87
Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis (1997) 2.53
Clostridium difficile: history of its role as an enteric pathogen and the current state of knowledge about the organism. Clin Infect Dis (1994) 2.51
Characterization of a toxin A-negative, toxin B-positive strain of Clostridium difficile responsible for a nosocomial outbreak of Clostridium difficile-associated diarrhea. J Clin Microbiol (2000) 2.50
Epidemiology of Clostridium difficile in infants. J Infect Dis (1982) 2.20
Multicenter evaluation of the Clostridium difficile TOX A/B TEST. J Clin Microbiol (1998) 2.09
Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis (1996) 2.04
Clostridium difficile infection associated with antineoplastic chemotherapy: a review. Clin Infect Dis (1993) 1.81
The effect of probiotics on Clostridium difficile diarrhea. Am J Gastroenterol (2000) 1.72
Nosocomial outbreak of Clostridium difficile-associated diarrhoea due to a clindamycin-resistant enterotoxin A-negative strain. Eur J Clin Microbiol Infect Dis (2001) 1.71
p38 MAP kinase activation by Clostridium difficile toxin A mediates monocyte necrosis, IL-8 production, and enteritis. J Clin Invest (2000) 1.68
Acute abdomen as the first presentation of pseudomembranous colitis. Gastroenterology (1991) 1.62
Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut (1986) 1.61
Extracolonic manifestations of Clostridium difficile infections. Presentation of 2 cases and review of the literature. Medicine (Baltimore) (2001) 1.59
Comparison of four commercially available rapid enzyme immunoassays with cytotoxin assay for detection of Clostridium difficile toxin(s) from stool specimens. J Clin Microbiol (1994) 1.56
Timing of surgery for fulminating pseudomembranous colitis. Br J Surg (1998) 1.45
Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med (1989) 1.41
Approach to patients with multiple relapses of antibiotic-associated pseudomembranous colitis. Am J Gastroenterol (1985) 1.40
Clostridium difficile colitis: an increasing hospital-acquired illness. Am J Surg (1995) 1.32
Clostridium difficile. Gastroenterol Clin North Am (2001) 1.28
Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol (1987) 1.23
Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology (1985) 1.18
Clostridium difficile-associated diarrhea and colitis: clinical manifestations, diagnosis, and treatment. Dis Colon Rectum (1998) 1.13
Disease associated with Clostridium difficile infection. Ann Intern Med (1989) 1.12
Pathogenesis of Clostridium difficile-associated diarrhoea. Eur J Gastroenterol Hepatol (1996) 1.10
Antibiotics and Clostridium difficile diarrhea in the ambulatory care setting. Clin Ther (2000) 1.10
Role of surgery in antibiotic-induced pseudomembranous enterocolitis. Am J Surg (1990) 1.05
Epidemic Clostridium difficile-associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol (1994) 1.04
Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea. A randomized double-blind trial. Arch Intern Med (1986) 1.00
Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother (1992) 1.00
Biological mode of action of Clostridium difficile toxin A: a novel enterotoxin. J Med Microbiol (1987) 0.98
Clinical and endoscopic findings in patients early in the course of clostridium difficile-associated pseudomembranous colitis. Am J Med (1985) 0.86
Conditions associated with leukocytosis in a tertiary care hospital, with particular attention to the role of infection caused by clostridium difficile. Clin Infect Dis (2002) 0.82
Fusidic acid for the treatment of antibiotic-associated colitis induced by Clostridium difficile. Infection (1984) 0.81
Intravascular danger signals guide neutrophils to sites of sterile inflammation. Science (2010) 5.84
Invasive potential of gut mucosa-derived Fusobacterium nucleatum positively correlates with IBD status of the host. Inflamm Bowel Dis (2011) 2.62
Activation of neuronal P2X7 receptor-pannexin-1 mediates death of enteric neurons during colitis. Nat Med (2012) 2.08
The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol (2010) 2.04
Opposing effects of smoking in ulcerative colitis and Crohn's disease may be explained by differential effects on dendritic cells. Inflamm Bowel Dis (2014) 2.03
Gallbladder polyps: epidemiology, natural history and management. Can J Gastroenterol (2002) 1.85
The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1β. Exp Physiol (2012) 1.85
NLRP3 inflammasome plays a key role in the regulation of intestinal homeostasis. Inflamm Bowel Dis (2010) 1.84
NK-cell enteropathy: a benign NK-cell lymphoproliferative disease mimicking intestinal lymphoma: clinicopathologic features and follow-up in a unique case series. Blood (2010) 1.83
Clostridium difficile toxin-induced inflammation and intestinal injury are mediated by the inflammasome. Gastroenterology (2010) 1.83
Assessment of endoscopic training of general surgery residents in a North American health region. Gastrointest Endosc (2008) 1.71
In vitro-derived alternatively activated macrophages reduce colonic inflammation in mice. Gastroenterology (2010) 1.61
Helicobacter pylori eradication: novel therapy for immune thrombocytopenic purpura? A review of the literature. Am J Hematol (2005) 1.56
PMNs facilitate translocation of platelets across human and mouse epithelium and together alter fluid homeostasis via epithelial cell-expressed ecto-NTPDases. J Clin Invest (2008) 1.35
Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Dis (2013) 1.25
Microscopic colitis -- a common cause of diarrhoea in older adults. Age Ageing (2010) 1.24
Postoperative complications and mortality following colectomy for ulcerative colitis. Clin Gastroenterol Hepatol (2011) 1.24
Inflammasome-independent NLRP3 augments TGF-β signaling in kidney epithelium. J Immunol (2012) 1.22
Chronic inflammatory diseases and cardiovascular risk: a systematic review. Can J Cardiol (2011) 1.21
The airway epithelium nucleotide-binding domain and leucine-rich repeat protein 3 inflammasome is activated by urban particulate matter. J Allergy Clin Immunol (2012) 1.17
Microscopic colitis-defining incidence rates and risk factors: a population-based study. Clin Gastroenterol Hepatol (2008) 1.13
Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm Bowel Dis (2010) 1.12
Polyunsaturated fatty acids in inflammatory bowel diseases: a reappraisal of effects and therapeutic approaches. Inflamm Bowel Dis (2013) 1.05
Hypoxia-inducible factor signaling provides protection in Clostridium difficile-induced intestinal injury. Gastroenterology (2010) 1.04
A pro-resolution mediator, prostaglandin D(2), is specifically up-regulated in individuals in long-term remission from ulcerative colitis. Proc Natl Acad Sci U S A (2010) 1.01
Evidence of endothelial dysfunction in patients with inflammatory bowel disease. Clin Gastroenterol Hepatol (2008) 1.00
Up-regulation of Annexin-A1 and lipoxin A(4) in individuals with ulcerative colitis may promote mucosal homeostasis. PLoS One (2012) 0.98
Mitogen-activated protein kinase pathways contribute to hypercontractility and increased Ca2+ sensitization in murine experimental colitis. Mol Pharmacol (2009) 0.98
Epidemiology of gastrointestinal stromal tumors in a defined Canadian Health Region: a population-based study. Int J Surg Pathol (2008) 0.96
Targeting hypoxia-inducible factor-1 (HIF-1) signaling in therapeutics: implications for the treatment of inflammatory bowel disease. Recent Pat Inflamm Allergy Drug Discov (2009) 0.94
TRPM8 activation attenuates inflammatory responses in mouse models of colitis. Proc Natl Acad Sci U S A (2013) 0.94
CD154-CD40 interactions drive hepatocyte apoptosis in murine fulminant hepatitis. Hepatology (2005) 0.93
Nucleotide-binding oligomerization domain-like receptors and inflammasomes in the pathogenesis of non-microbial inflammation and diseases. J Innate Immun (2011) 0.92
Octreotide treatment of massive hemorrhage due to cytomegalovirus colitis. Can J Gastroenterol (2003) 0.91
Nitric oxide increases Wnt-induced secreted protein-1 (WISP-1/CCN4) expression and function in colitis. J Mol Med (Berl) (2009) 0.90
The EGF receptor and HER2 participate in TNF-α-dependent MAPK activation and IL-8 secretion in intestinal epithelial cells. Mediators Inflamm (2012) 0.90
Intrarectal instillation of Clostridium difficile toxin A triggers colonic inflammation and tissue damage: development of a novel and efficient mouse model of Clostridium difficile toxin exposure. Infect Immun (2012) 0.89
Role of EP4 receptor and prostaglandin transporter in prostaglandin E2-induced alteration in colonic epithelial barrier integrity. Am J Physiol Gastrointest Liver Physiol (2010) 0.86
Lymphocytic colitis is associated with increased pro-inflammatory cytokine profile and up regulation of prostaglandin receptor EP4. PLoS One (2013) 0.85
Lymphocytic and collagenous colitis: the emerging entity of microscopic colitis. An update on pathophysiology, diagnosis and management. Can J Gastroenterol (2003) 0.84
Inflammatory bowel disease cause-specific mortality: a primer for clinicians. Inflamm Bowel Dis (2014) 0.84
Clostridium difficile infection worsens the prognosis of ulcerative colitis. Can J Gastroenterol Hepatol (2014) 0.84
Invasive amoebiasis: a review of Entamoeba infections highlighted with case reports. Can J Gastroenterol Hepatol (2014) 0.83
Helicobacter pylori activates calpain via toll-like receptor 2 to disrupt adherens junctions in human gastric epithelial cells. Infect Immun (2011) 0.83
Contribution of bone marrow-derived cells to the pro-inflammatory effects of protease-activated receptor-2 in colitis. Inflamm Res (2010) 0.82
The association between celiac disease and eosinophilic esophagitis in children and adults. BMC Gastroenterol (2013) 0.82
The P2Y6 receptor mediates Clostridium difficile toxin-induced CXCL8/IL-8 production and intestinal epithelial barrier dysfunction. PLoS One (2013) 0.82
Drug-induced inflammatory bowel disease and IBD-like conditions. Inflamm Bowel Dis (2013) 0.81
A prescription that addresses the decline of basic science education in medical school. Clin Invest Med (2014) 0.80
Evaluation of endoscopist and pathologist factors affecting the incidence of microscopic colitis. Can J Gastroenterol (2012) 0.79
Diagnosis of portal hypertensive gastropathy. Curr Opin Gastroenterol (2003) 0.79
The risk of microscopic colitis in solid-organ transplantation patients: a population-based study. Transplantation (2008) 0.79
MAP kinase activation increases BK polyomavirus replication and facilitates viral propagation in vitro. J Virol Methods (2010) 0.79
Profiles of Lamina Propria T Helper Cell Subsets Discriminate Between Ulcerative Colitis and Crohn's Disease. Inflamm Bowel Dis (2016) 0.79
Microscopic colitis: a review for the surgical endoscopist. Can J Surg (2009) 0.78
Vitamin D₃ metabolites enhance the NLRP3-dependent secretion of IL-1β from human THP-1 monocytic cells. J Cell Biochem (2015) 0.78
Novel CD8+ T-Cell Subsets Demonstrating Plasticity in Patients with Inflammatory Bowel Disease. Inflamm Bowel Dis (2016) 0.78
iNOS in cardiac myocytes plays a critical role in death in a murine model of hypertrophy induced by calcineurin. Am J Physiol Heart Circ Physiol (2008) 0.77
A potential new tool for managing Clostridium difficile infection. J Infect Dis (2013) 0.75
Predictors of mortality among patients undergoing colectomy for ischemic colitis: A population-based United States study. Can J Gastroenterol Hepatol (2014) 0.75
There may be a way to say "NO" to gastric injury associated with the combined use of aspirin and cyclooxygenase-2 inhibitors. Can J Gastroenterol (2004) 0.75
Celiac disease. CME update for family physicians. Can Fam Physician (2004) 0.75
Highlights from the 6th Annual University of Calgary Leaders in Medicine Research Symposium and the Keynote Address by Dr. Danuta Skowronski. Clin Invest Med (2015) 0.75
Multiple lymphomatous diverticulosis and comorbid chronic lymphocytic leukemia: novel manifestations of ileocolic mantle cell lymphoma. Int J Surg Pathol (2007) 0.75
Proceedings from the 6th Annual University of Calgary Leaders in Medicine Research Symposium. Clin Invest Med (2015) 0.75
Effects of nitric oxide and reactive oxygen species on HIF-1α stabilization following clostridium difficile toxin exposure of the Caco-2 epithelial cell line. Cell Physiol Biochem (2013) 0.75